Related Experiment Video
Updated: Jul 26, 2025
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
Glycolysis-based drug delivery nanosystems for therapeutic use in tumors and applications
Chenchen Geng1, Siyan Pang1, Ruyin Ye1
1Department of Biotechnology, Bengbu Medical College, Anhui Province Key Laboratory of Translational Cancer Research, Bengbu Medical College, Anhui 233030, China.
Abstract:
Tumor cells are able to use glycolysis to produce energy under hypoxic conditions, and even under aerobic conditions, they rely mainly on glycolysis for energy production, the Warburg effect. Conventional tumor therapeutic drugs are unidirectional, lacking in targeting and have limited therapeutic effect. The development of a large number of nanocarriers and targeted glycolysis for the treatment of tumors has been extensively investigated in order to improve the therapeutic efficacy. This paper reviews the research progress of nanocarriers based on targeting key glycolytic enzymes and related transporters, and combines nanocarrier systems with other therapeutic approaches to provide a new strategy for targeted glycolytic treatment of tumors, providing a theoretical reference for achieving efficient targeted treatment of tumors.
Insights
This review explores nanocarriers targeting tumor glycolysis, like the Warburg effect. Combining nanocarriers with other therapies offers a new strategy for efficient, targeted cancer treatment.
Area of Science:
- Biochemistry
- Oncology
- Nanomedicine
Background:
- Tumor cells exhibit the Warburg effect, utilizing glycolysis for energy even in aerobic conditions.
- Conventional cancer therapies often lack specificity and have limited efficacy.
- Targeting tumor-specific metabolic pathways like glycolysis is a promising therapeutic strategy.
Purpose of the Study:
- To review nanocarrier-based strategies for targeting key glycolytic enzymes and transporters in tumors.
- To explore the combination of nanocarrier systems with other therapeutic modalities for enhanced tumor treatment.
- To provide a theoretical basis for efficient and targeted glycolytic therapy in oncology.
Main Methods:
- Review of current research on nanocarriers designed to target glycolytic pathways.
- Analysis of studies combining nanocarrier systems with other cancer treatment approaches.
- Synthesis of information on targeting key enzymes and transporters involved in tumor glycolysis.
Main Results:
- Nanocarriers show potential for targeted delivery to tumor cells, exploiting their altered metabolism.
- Combining nanocarrier-based glycolysis targeting with other therapies can improve therapeutic outcomes.
- Significant progress has been made in developing nanocarrier systems for targeted cancer glycolysis inhibition.
Conclusions:
- Targeting tumor glycolysis with nanocarriers represents a promising avenue for cancer therapy.
- Combination strategies involving nanocarriers offer a novel approach to overcome limitations of conventional treatments.
- Further research into nanocarrier systems can lead to more efficient and targeted cancer treatment modalities.
